Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Paying user area
Try for free
Pfizer Inc. pages available for free this week:
- Statement of Comprehensive Income
- Common-Size Income Statement
- Common-Size Balance Sheet: Assets
- Analysis of Solvency Ratios
- Enterprise Value (EV)
- Present Value of Free Cash Flow to Equity (FCFE)
- Return on Equity (ROE) since 2005
- Return on Assets (ROA) since 2005
- Price to Earnings (P/E) since 2005
- Analysis of Revenues
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Pfizer Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Long-term Activity Ratios (Summary)
Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
The investment activity ratios exhibit a synchronized pattern characterized by a significant decline throughout 2022 and 2023, reaching a nadir in the first quarter of 2024, followed by a period of relative stability and marginal recovery through June 2026.
- Net Fixed Asset Turnover
- A peak of 6.64 was recorded in July 2022, followed by a sustained downward trend that bottomed out at 2.97 in June 2024. Following this contraction, the ratio entered a stabilization phase, fluctuating within a narrow band between 3.24 and 3.46, and concluding the period at 3.35 in June 2026.
- Total Asset Turnover
- Efficiency in total asset utilization decreased from a high of 0.52 in July 2022 to a minimum of 0.25 by March 2024. A gradual recovery was observed from late 2024 onward, with the ratio stabilizing between 0.30 and 0.32 for the final six quarters of the analyzed period.
- Equity Turnover
- The ratio of revenue to equity mirrored the broader asset trends, declining from 1.16 in July 2022 to a low of 0.61 in March 2024. Subsequently, a moderate recovery occurred, with the ratio trending upward to end at 0.75 in June 2026.
The simultaneous decline across all turnover metrics between mid-2022 and early 2024 suggests a period of significant balance sheet expansion or a reduction in revenue generation relative to the investment base. The subsequent plateauing of these ratios indicates that the organization has reached a new operational equilibrium, where the utilization of fixed assets, total assets, and equity has stabilized at a lower efficiency level compared to the 2022 peak.
Net Fixed Asset Turnover
| Jun 28, 2026 | Mar 29, 2026 | Dec 31, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 31, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Revenues | ||||||||||||||||||||||||
| Property, plant and equipment, net of accumulated depreciation | ||||||||||||||||||||||||
| Long-term Activity Ratio | ||||||||||||||||||||||||
| Net fixed asset turnover1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| Net Fixed Asset Turnover, Competitors2 | ||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q2 2026 Calculation
Net fixed asset turnover
= (RevenuesQ2 2026
+ RevenuesQ1 2026
+ RevenuesQ4 2025
+ RevenuesQ3 2025)
÷ Property, plant and equipment, net of accumulated depreciation
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The analysis of the net fixed asset turnover ratio reveals a significant contraction in asset productivity between the second quarter of 2022 and the first half of 2024, followed by a period of relative stabilization through mid-2026.
- Revenue Trends
- A substantial decline in quarterly revenues is observed, starting from a peak of 27,742 million US dollars in July 2022 and falling to a low of 13,007 million US dollars by July 2023. While a moderate recovery occurred throughout 2024 and 2025, with revenues fluctuating between 13,283 million and 17,763 million US dollars, they remained significantly below the levels recorded in early 2022.
- Fixed Asset Investment
- Property, plant, and equipment, net of accumulated depreciation, exhibited a consistent upward trend from April 2022 (15,109 million US dollars) through December 2023 (18,940 million US dollars). Following this period of expansion, the fixed asset base remained relatively stable, oscillating between 18,347 million and 19,402 million US dollars through June 2026.
- Net Fixed Asset Turnover Interpretation
- The net fixed asset turnover ratio experienced a sharp decline from a high of 6.64 in July 2022 to a trough of 2.97 in June 2023. This deterioration was driven by the simultaneous occurrence of falling revenues and an increasing investment in fixed assets, indicating a decrease in the efficiency of the company's long-term asset base in generating sales. From late 2023 through mid-2026, the ratio stabilized, fluctuating within a narrow range between 2.98 and 3.46, suggesting that the asset utilization rate reached a new equilibrium as revenue volatility subsided and capital expenditures leveled off.
Total Asset Turnover
| Jun 28, 2026 | Mar 29, 2026 | Dec 31, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 31, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Revenues | ||||||||||||||||||||||||
| Total assets | ||||||||||||||||||||||||
| Long-term Activity Ratio | ||||||||||||||||||||||||
| Total asset turnover1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| Total Asset Turnover, Competitors2 | ||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q2 2026 Calculation
Total asset turnover
= (RevenuesQ2 2026
+ RevenuesQ1 2026
+ RevenuesQ4 2025
+ RevenuesQ3 2025)
÷ Total assets
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The total asset turnover ratio exhibits a distinct three-phase trajectory characterized by initial stability, a sharp contraction, and a subsequent period of gradual stabilization. This trend reflects a significant shift in the efficiency with which assets are utilized to generate revenue.
- Revenue and Asset Correlation
- A period of high operational efficiency is observed in the first half of 2022, where revenues peaked at 27.7 billion USD against a total asset base of approximately 195 billion USD. However, a misalignment occurred throughout 2023, as revenues declined sharply to a low of 13.0 billion USD in July 2023, while total assets simultaneously increased, reaching a peak of 226.5 billion USD by December 2023. This inverse movement between revenue generation and asset accumulation drove the precipitous drop in the turnover ratio.
- Analysis of the Asset Turnover Ratio
- The turnover ratio remained consistently above 0.50 during early 2022, indicating a relatively efficient conversion of assets into sales. A severe deterioration followed, with the ratio falling to 0.26 by December 2023 and hitting a nadir of 0.25 in March 2024. This decline represents a substantial reduction in asset productivity.
- Recovery and Stabilization Phase
- From mid-2024 through mid-2026, a modest recovery is evident. The ratio climbed from 0.26 to a stabilized range between 0.30 and 0.32. This improvement is attributed to a combination of recovering quarterly revenues—reaching as high as 17.7 billion USD in late 2024—and a strategic reduction in the total asset base, which declined from its 2023 peak to approximately 201 billion USD by June 2026.
Equity Turnover
| Jun 28, 2026 | Mar 29, 2026 | Dec 31, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 31, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Revenues | ||||||||||||||||||||||||
| Total Pfizer Inc. shareholders’ equity | ||||||||||||||||||||||||
| Long-term Activity Ratio | ||||||||||||||||||||||||
| Equity turnover1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| Equity Turnover, Competitors2 | ||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q2 2026 Calculation
Equity turnover
= (RevenuesQ2 2026
+ RevenuesQ1 2026
+ RevenuesQ4 2025
+ RevenuesQ3 2025)
÷ Total Pfizer Inc. shareholders’ equity
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The analysis of equity turnover reveals a significant shift in capital efficiency from early 2022 through mid-2026. An initial period of high asset utilization was followed by a sharp contraction, eventually transitioning into a period of stabilization at a lower baseline.
- Revenue Trajectory
- A notable volatility in top-line performance is observed. Revenues peaked in early 2022, reaching $27.7 billion in July 2022, before experiencing a substantial decline through 2023, where values dropped to as low as $13.0 billion. From 2024 through mid-2026, revenues exhibited a partial recovery and stabilization, generally fluctuating between $13.2 billion and $17.7 billion.
- Shareholders' Equity Evolution
- The equity base showed a consistent upward trend during the first year of the period, rising from $82.4 billion in April 2022 to a peak of $100.9 billion in April 2023. Following this peak, shareholders' equity entered a period of gradual contraction and fluctuation, settling into a range between $85.1 billion and $92.8 billion from 2024 onwards.
- Equity Turnover Ratio Dynamics
- The equity turnover ratio demonstrates a strong negative correlation with the expansion of the equity base and the contraction of revenues. The ratio declined from a high of 1.16 in July 2022 to a low of 0.61 by March 2024. This downturn indicates a reduction in the company's ability to generate sales relative to its equity investment during this window.
- Stabilization and Recovery Patterns
- Starting in the second quarter of 2024, the turnover ratio ceased its precipitous decline and began to stabilize. Between June 2024 and June 2026, the ratio fluctuated within a narrow band of 0.64 to 0.75. This suggests a realignment of the company's operational scale with its capital structure, resulting in a more consistent, albeit lower, level of equity efficiency compared to 2022 levels.